(VIANEWS) – Shares of INVENTIVA (CAC 40: IVA.PA) fell by a staggering 10.48% to €1.96 at 11:54 EST on Wednesday, following the last session’s downward trend. CAC 40 is sliding 0.77% to €7,473.53, after two successive sessions in a row of losses. This seems, at the moment, a somewhat down trend trading session today.
About INVENTIVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Earnings Per Share
As for profitability, INVENTIVA has a trailing twelve months EPS of €-1.3.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, INVENTIVA’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for INVENTIVA is 134314 which is 199.99% above its average volume of 44772.
More news about INVENTIVA (IVA.PA).
